期刊文献+

罕见病当前国际政策及现状介绍 被引量:25

Introduction of Current International Policies and Situation of the Rare Diseases
下载PDF
导出
摘要 目的:为我国罕见病医疗保障和用药法规的建立提供借鉴和参考。方法:介绍和分析不同国家和地区对罕见病及其药物开发的政策。结果:各主要发达国家在药品注册方面和管理方面都有一套相关政策.包括对孤儿药的认定及其开发研究的鼓励政策,值得我国在孤儿药品注册和药品管理政策制定时借鉴和参考。结论:明确罕见病的定义.制定激励措施对罕见病的研究进展有很大的推动作用。 Objective: To provide the reference for establishing the policy of rare disease and orphan drugs in China. Methods: Analyzing incentive measures for the development of orphan drugs in different countries and regions. Results: The major developed countries have a set of related policies in the medical registration and management aspects, including the identification of orphan drugs and its development policy, it is worth of learning.Conclusions: Definiting the rare diseases and making incentive measures can encourage the research and development of rare diseases.
出处 《药品评价》 CAS 2010年第22期48-51,共4页 Drug Evaluation
关键词 罕见病 孤儿药 政策 激励措施 Rare Diseases Orphan Drugs Policy Incentive Measures
  • 相关文献

参考文献10

  • 1张延军,王静波,郭剑非.美国孤儿药法案及其对新药研发的影响[J].中国药物经济学,2010,5(1):27-34. 被引量:15
  • 2许关煜,李敏华.国外罕见病用药研究开发动态[J].上海医药,2004,25(1):33-35. 被引量:2
  • 3罕见病政策与法规[OL].中国罕见病网.http://www.chinararedisease.cn/5-l.hunl.
  • 4FDA.Cumulative List Designated Approved Orphan Products[OL].http://wwwrarediseases.org/.2009-05-05.
  • 5王海英.美国药品申报与法规管理[M].北京:中国医药科技出版社.2005.69-70.
  • 6FDA-Tax Credit for Testing Expenses for Drugs for Rare Diseases or Conditions.[OL].http://fda.gov/Forlndustry[DevelopingProductsf orRareDiseawsConditions/Incentives/default.htm.
  • 7EMEA.Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products[OL].全球法规网http://policy.mofcom.gov.cn/PDFView?id=fel787ee-5965-4de1-88de-7ed81830bece&libcode=flaw.[2000-1-22].
  • 8林禹鸿.台湾罕见疾病防治与药物法的启示[C].2009年中国药学会药事管理专业委员会年会暨"国家药物政策与《药品管理法》修订研究"论坛论文集,2009:117-124.
  • 9台湾罕见疾病个案特殊营养品与罕见疾病药物流中心.[OL].http://www.rdfdlmc.tw/.[2009-6-24].
  • 10杨俊坚.保障体系奠定罕见病用药市场基础[OL].医药经济报.http://www.yyjjb.com/htmU2010-11/22/conten_129815.htm.[2010-11-22].

二级参考文献27

  • 1Schieppati A,enter J I,Daina E,et al.Why rare diseases are an important medical and social issue[J].Lancet,2008,371(9629):2039-2041.
  • 2MacLeod S.Optimal therapy for rare disorders and genetic diseases:ethical and political challenges[J].Proc West Pharmacol Soc,2007,50:21-23.
  • 3关于尽快出台"罕见病"立法及完善相关保障政策的建议[OL].[2010-1-2].http://hi.baidu.com/kallmann/blog/item/edf878ed834f8fdcb31cb1f5.html.
  • 4让苯丙酮尿症孩子用上"孤儿药".北京晚报,2009-5-15(38)[2010-1-1].Http://newepaper.bjd.com.cn/bjwb/page/81/2009-05/15/38/2009051538_pdf.Pdf.
  • 5Haffner M E,Whitley J,and Moses M.Two decades of orphan product development[J].Nat Rev Drug Diseov,2002,1(10):821-825.
  • 6Schweitzer S O.Pharmaceutical Economics and Policy[M].2nd ed.New York:Oxford University Press.2007:39-41,160.
  • 7Haffner M E.The Food and Drug Administration's Office of Orphan Products Development:incentives,grants,and special designations speed therapies for orphan diseases[J].Retina,2005,25(8 Suppl):S89-S90.
  • 8Remuzzi G and Garattini S.Rare diseases:what's next?[J].Lancet,2008,371(9629):1978-1979.
  • 9Heemstra H E,de Vrueh RL,van Weely S,et al.Orphan drug development across Europe:bottlenecks and opportunities[J].Drug Diseov Today,2008,13(15-16):670-676.
  • 10Haffner M E,Torrent-Farnell J,and Matter P D.Does orphan drug legislation really answer the needs of patients?[J].Lancet,2008,371(9629):2041-2044.

共引文献16

同被引文献211

引证文献25

二级引证文献159

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部